Free Newsletter
FEATURES >> The most interesting logos in Pharma
Amid closures and cuts, Genentech starts building
While news has been flying about Pfizer and Merck's cost-cutting and real estate moves since their respective mergers with Wyeth and Schering-Plough, Roche quietly has been shifting jobs and operations, too. The latest: Roche's Genentech unit is going forward on a new building on its South San Francisco campus, at a time when it's moving some jobs to the area from other sites.
Roche bought out the share of Genentech it didn't already own last year. Since then, the Swiss drugmaker has made plenty of changes, including a two-phased management shuffle and the closure of some New Jersey facilities and an R&D site in Palo Alto. Roche also laid off workers as it sought to cut costs and streamline its post-merger operations.
To date, the company has cut $1 billion in costs and moved a host of jobs to South San Francisco, Roche's Erich Hunziker told the J.P. Morgan Healthcare Conference in San Francisco. And now it's ready to go forward with a long-held plan to add a third office building to that campus.
- Read the San Francisco Business Times story
Related Articles:
Genentech brand to replace Roche in U.S.
Nail-biting at Genentech as layoffs start
Roche execs take Genentech reins
Comments
The article says that Roche will add a 3rd building to the campus. That sort of implies that Genentech only has 2 buildings, which for anyone who has been to the campus recently knows is not accurate. The new building will likely bring the grand total number of buildings on campus to somewhere around 30, not 3.
3rd office building. The other buildings are labs/ production facilities
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities



SHARE
WITH: